An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD.
about
New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analysesA review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities.Hospital costs associated with pediatric burn injury.COPD a social disease: inappropriateness and pharmaco-economics. The role of the specialist: present and future.Adherence to Oral Therapy for Urgency Urinary Incontinence: Results from the Anticholinergic Versus Botox Comparison (ABC) TrialCOPD--the primary care perspective: addressing epidemiology, pathology, diagnosis, treatment of smoking's multiple morbidities and the patient's perspective.Optimizing economic outcomes in the management of COPD.Role of tiotropium in the treatment of COPD.Assessing treatment effects of inhaled corticosteroids on medical expenses and exacerbations among COPD patients: longitudinal analysis of managed care claims.Socioeconomic gradients in tiotropium use among adults with COPD.Treating COPD with PDE 4 inhibitors.Sequential comparison of tiotropium to high-dose ipratropium in patients with chronic obstructive pulmonary disease in a practice setting.Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues.Integrating values and consumer involvement in guidelines with the patient at the center: article 8 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.Cost-effectiveness of pharmacotherapy for COPD in ambulatory care: a review.Costs of Treatment of Chronic Obstructive Pulmonary Disease.
P2860
Q30419928-0BA4A0D9-391D-456E-9288-5A5CF1C07A82Q33732066-03B7DBEC-36D0-4658-AEE9-7EADCAEAEDB3Q34589407-03C61F54-68C7-492F-89CD-0FD8852342A1Q36293842-EAF970C0-63B0-4379-A25A-E07908032709Q36386201-9C89269E-8D96-488B-8DB4-33621F4BD2A4Q36761477-906D82B5-A3D9-45FB-AFA5-27F2829DE562Q36859405-C2C1B9E8-DEAE-44BA-9026-2BF5CF7A43D9Q37017516-F7799495-D48C-4FA6-BFA9-F2327EBCEBDDQ37037387-327D5709-324B-47AC-A88E-D85BA0BE3A8BQ37070328-1113BB91-4F76-4982-8ADC-8579E25E3838Q37082594-50A87568-4FB3-44AF-A33F-59DAF57EE3AAQ37408475-BDDEEACC-B2A7-4960-A14F-C0475DBF67D0Q37992679-9585034D-EACC-4591-BAB4-B8D421804F77Q38068888-D05A3D39-DA13-46FF-ACA5-8201AC8532A4Q38099359-13E537EC-7344-4AFF-A024-89FF965022CFQ40072084-BE12B288-564C-405F-89B3-FFBC252BAD88
P2860
An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD.
@ast
An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD.
@en
type
label
An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD.
@ast
An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD.
@en
prefLabel
An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD.
@ast
An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD.
@en
P2093
P356
P1433
P1476
An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD.
@en
P2093
Anna O D'Souza
Jan Kavookjian
Lesley Ann Miller
Michael J Smith
P304
P356
10.1378/CHEST.129.6.1693
P407
P577
2006-06-01T00:00:00Z